Source: ET
Moderna Inc.’s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.
TRENDING: US Airline Lobbying Group Warns Of ‘Catastrophic Disruptions’ Upon 5G Rollout
